Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Simcere Pharmaceutical Group Limited ( (HK:2096) ) just unveiled an update.
Simcere Pharmaceutical Group Limited announced the acceptance of its new drug application for Deunoxavir Marboxil Tablets by China’s National Medical Products Administration. This anti-influenza drug, developed in collaboration with Jiaxing AnDiCon Biotech Co., Ltd., shows promise in treating influenza A and B with a single tablet dosage. The acceptance marks a significant step forward in Simcere’s efforts to expand its market presence in China, potentially benefiting a wide range of patients, including children, due to its safety and efficacy profile. The company has exclusive commercialization rights in China, and the drug’s clinical trials have shown statistically significant improvements in symptom relief.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs. The company collaborates with partners like Jiaxing AnDiCon Biotech Co., Ltd. to enhance its portfolio, particularly in the fields of respiratory, anti-infection, and analgesia.
YTD Price Performance: 11.69%
Average Trading Volume: 4,703,839
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$19.72B
Learn more about 2096 stock on TipRanks’ Stock Analysis page.